A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

June 15, 2017

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2027

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

Azacitidine

Azacitidine solution is administered intravenously (IV) over a period of 10-40 minutes.

DRUG

Decitabine

Administered intravenously (IV) over approximately one hour.

DRUG

Cytarabine

Given IV or intrathecally (IT).

DRUG

Daunorubicin

Given IV.

DRUG

Etoposide

Given IV.

COMBINATION_PRODUCT

ITMHA

Given IT.

DRUG

Idarubicin

Given IV.

DRUG

Fludarabine

Given IV over approximately 30 minutes.

DRUG

Mitoxantrone

Given IV.

DRUG

Erwinia asparaginase

Given IV or intramuscularly (IM).

DRUG

Sorafenib

Given PO.

DRUG

G-CSF

Given IV.

DRUG

Dexrazoxane

Given IV immediately before idarubicin administration.

BIOLOGICAL

Stem Cell Transplant

The transplant protocol will depend on the patient's donor and transplant physician's preference.

DRUG

Asparaginase Erwinia Chrysanthemi, Recombinant-Rywn

May be used in the event of an Erwinia asparaginase shortage. Given intramuscularly (IM).

Trial Locations (10)

38105

St. Jude Children's Research Hospital, Memphis

48201

Children's Hospital of Michigan, Detroit

57117

Sanford Children's Specialty Clinic, Sioux Falls

60637

University of Chicago Children's Hospital (Comer), Chicago

76104

Cook Children's Medical Center, Fort Worth

92123

Rady Children's Hospital and Health Center, San Diego

92968

Children's Hospital of Orange County, Orange

93636

Children's Hospital of Central California, Madera

94304

Lucile Packard Children's Hospital Stanford University, Palo Alto

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

St. Jude Children's Research Hospital

OTHER